Spring 2026 brought a wave of claims that “peptides are legal again.” Most of that talk is about other molecules. Sermorelin sits in a different part of FDA’s compounding rules from the peptides that moved, and the documents that changed this year barely touch it. What follows is each of those documents, read directly, and what it means for someone with a sermorelin prescription.
Is sermorelin legal to buy with a prescription?
Yes. The legal route is a prescription from a licensed clinician, filled by a licensed compounding pharmacy or an FDA-registered outsourcing facility. Federal law lets a pharmacy compound from a bulk ingredient in three cases: the ingredient meets an official USP monograph, it is a component of an FDA-approved drug, or it appears on FDA’s 503A bulks list [4]. FDA’s own 503B nominations list places sermorelin acetate in Category 1 and marks it as a component of an FDA-approved drug [3], a reference to Geref, the sermorelin product approved in 1990 and later discontinued for reasons unrelated to safety [6].
That is legal, not approved. A compounded drug is made to order and is not reviewed by FDA before it ships, a distinction the FDA approval history works through. States license and inspect the pharmacies, so availability can still vary by state, and a reputable prescriber will tell you during intake whether they can ship to yours.
What changed for peptides in April 2026?
FDA keeps a public page of bulk substances that it says may present significant safety risks when compounded, known as Category 2. As of the FDA page updated April 22, 2026, a long list of peptides sits in its second table, headed “nominated but withdrawn”: BPC-157, CJC-1295, GHK-Cu for injectable routes, KPV, MOTs-C, semax, selank, epitalon, emideltide (DSIP), melanotan II, AOD-9604 and others [1]. Ipamorelin is listed there too, while remaining in Category 2 for outsourcing facilities under section 503B.
Two details keep that from being the green light it sounds like. First, the page says these entries were withdrawn by the nominators, the companies that had asked FDA to evaluate them, and it still prints FDA’s safety concerns beside each one. Second, leaving Category 2 does not put a substance on the list of what pharmacies may compound. For ipamorelin, FDA’s 2024 evaluation found no USP monograph, found that it is not a component of any approved drug, and recommended against adding it to the 503A bulks list [9].
GHK-Cu shows how fast the lists move. FDA’s 503A nominations list records that GHK-Cu was removed from Category 1 on April 22, 2026, after its nominations were withdrawn; that one nominator then clarified on May 5 that it had meant to withdraw only the injectable route; and that GHK-Cu for non-injectable routes goes back into Category 1, with an advisory committee consultation planned before the end of February 2027 [2]. Products that combine the two, such as sermorelin with GHK-Cu, sit across that line.
Was sermorelin ever on the Category 2 list?
It does not appear anywhere on the Category 2 page, in the current table or in the withdrawn one [1]. It is also absent from all three 503A nomination categories, as updated May 14, 2026 [2]. That is consistent with its standing on the 503B list: a component of an approved drug does not need a place on the 503A bulks list to be compounded [3] [4]. So the April changes did not move sermorelin: it was not in the part of the system that moved.
What did FDA’s July 2026 compounding advisory meeting review?
A Federal Register notice published April 16, 2026 scheduled FDA’s Pharmacy Compounding Advisory Committee for July 23 and 24, 2026, to discuss seven peptides for the 503A bulks list: BPC-157 (evaluated for ulcerative colitis), KPV, TB-500, MOTs-C, emideltide, semax and epitalon [4]. Sermorelin was not on the agenda [5]. FDA’s meeting page posts the briefing documents, the questions, the agenda and the agency’s slides; an advisory vote is advice to FDA, not a decision, and no final determination on those seven is posted there [5].
A search of the Federal Register for FDA documents published in 2026 that mention sermorelin returns none. The same search for “bulk drug substances” returns ten, including the July meeting notice, so the search itself works. The 2026 notices on the 503B clinical-need list concern semaglutide, tirzepatide and liraglutide, not sermorelin.
Is “research-use” sermorelin legal?
It sits outside everything above. The compounding exemptions cover drugs compounded by a licensed pharmacist or physician, or by a registered outsourcing facility [4]. A vial sold online as a research chemical and labeled not for human consumption is none of those. It comes with no prescription, no pharmacy accountable for its contents and no requirement that what is in the vial matches the label. The practical and legal differences are set out in prescribed vs. research-chemical sermorelin, and what a real pharmacy should be able to show you is in how to read a certificate of analysis.
Is sermorelin a controlled substance or a PED?
It is not a controlled substance: it does not appear in the federal schedules in 21 CFR part 1308 [7]. It is a performance-enhancing drug under sport rules, prohibited at all times by the World Anti-Doping Agency under section S2 [8]. Both answers, and why “not scheduled” is not the same as “unregulated,” are covered in whether sermorelin is a steroid, a PED or a controlled substance.
What would change sermorelin’s status next?
Three things are worth watching. The first is the 503B list itself: sermorelin acetate is in Category 1, “under evaluation,” and a final FDA decision to include or exclude it would be published in the Federal Register [3]. The second is the approved product. FDA’s 503B list notes that it does not intend to act against an outsourcing facility for compounding a copy of an approved drug that has been discontinued and is no longer marketed, which is Geref’s position today [3]; a returning approved sermorelin would change that arithmetic. The third is the pharmacy: a compounder that fails inspection or receives a warning letter changes what one seller can supply, which is why knowing who makes your sermorelin matters more than any headline.
None of the 2026 documents points at sermorelin. The peptides they do cover, and how the two classes of growth hormone peptides compare, are mapped in growth hormone peptides, and the most common combination question is answered in sermorelin and ipamorelin together.